Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | DTYMK | P23919 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.40 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | JAK1 | P23458 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2950039 | 0.89 | POLB (0.47) | GRM5GRM1POLBDTYMKGPR119 | |
| SCHEMBL10125419 | 0.86 | POLB (0.43) | GRM5GRM1POLBDTYMKGPR119 | |
| SCHEMBL10125364 | 0.84 | GPR119 (0.42) | GRM5POLBDTYMKGPR119JAK2 | |
| SCHEMBL15033814 | 0.82 | GRM5 (0.40) | GRM5POLBDTYMKGPR119JAK2 | |
| SCHEMBL5252770 | 0.82 | ALDH1A1 (0.35) | GRM1 | |
| SCHEMBL3886709 | 0.80 | GPR119 (0.46) | GRM5GRM1POLBDTYMKGPR119 | |
| SCHEMBL2904485 | 0.80 | POLB (0.46) | GRM5GRM1POLBDTYMKGPR119 | |
| SCHEMBL10125429 | 0.79 | POLB (0.41) | GRM5POLBDTYMKGPR119SQOR | |
| SCHEMBL28742403 | 0.78 | GPR119 (0.37) | GRM5GRM1GPR119JAK2JAK1 | |
| SCHEMBL26923185 | 0.77 | GPR119 (0.43) | GRM5GRM1POLBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831201-B1 | PIPERIDINE AND AZETIDINE DERIVATIVES AS GLYT1 INHIBITORS | MERCK SHARP & DOHME (GB) | 2010-08-04 | — | — | EP | disclosed |
| US-7655644-B2 | Piperidine and azetidine derivatives as GlyT1 inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-02-02 | — | — | US | disclosed |
| US-20080090796-A1 | Piperidine And Azetidine Derivatives As Glyt1 Inhibitors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090796-A1 | Piperidine And Azetidine Derivatives As Glyt1 Inhibitors | SLC6A7, SLC1A1, SLC1A2 | GRM5 390/4885GRM1 62/4885POLB 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.